Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ARTL Artelo Biosciences, Inc. daily Stock Chart
ARTL [NASD]
Artelo Biosciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.24 Insider Own19.20% Shs Outstand3.43M Perf Week-4.20%
Market Cap4.92M Forward P/E- EPS next Y-1.64 Insider Trans0.00% Shs Float2.50M Perf Month7.87%
Income-3.90M PEG- EPS next Q-0.40 Inst Own0.40% Short Float0.15% Perf Quarter18.11%
Sales- P/S- EPS this Y-336.10% Inst Trans7.49% Short Ratio0.02 Perf Half Y-41.95%
Book/sh1.08 P/B1.27 EPS next Y-0.60% ROA-89.20% Target Price- Perf Year30.48%
Cash/sh0.56 P/C2.46 EPS next 5Y- ROE-108.40% 52W Range0.61 - 5.00 Perf YTD-49.26%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.60% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin- 52W Low124.59% ATR0.21
Employees3 Current Ratio4.80 Sales Q/Q- Oper. Margin- RSI (14)54.95 Volatility25.58% 16.43%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume3.20 Prev Close1.63
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume180.79K Price1.37
Recom2.00 SMA206.61% SMA5017.98% SMA200-25.41% Volume578,941 Change-15.95%
Jun-03-20 09:30AM  
Artelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences
GlobeNewswire -15.95%
09:00AM  
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
ACCESSWIRE
May-12-20 09:30AM  
Artelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
GlobeNewswire -9.63%
May-06-20 09:09AM  
Independent Chairperson of the Board Connie Matsui Just Bought 278% More Shares In Artelo Biosciences, Inc. (NASDAQ:ARTL)
Simply Wall St.
Apr-14-20 08:30AM  
Artelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update
GlobeNewswire +31.43%
Mar-23-20 09:00AM  
Artelo Biosciences to Present at the Spring Investor Summit on March 25th
ACCESSWIRE +18.56%
Mar-02-20 09:07AM  
Here's Why We're A Bit Worried About Artelo Biosciences's (NASDAQ:ARTL) Cash Burn Situation
Simply Wall St. +24.77%
Feb-24-20 09:00AM  
Artelo Biosciences to Present at Biocoms 10th Annual Global Life Sciences Partnering Conference
GlobeNewswire
Feb-03-20 11:42AM  
Artelo's stock soars after NCI grant to develop cancer treatment
MarketWatch +35.47%
08:30AM  
Artelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
GlobeNewswire
Jan-29-20 09:00AM  
Artelo Biosciences to Present at the LSX World Congress in London
GlobeNewswire
Jan-14-20 08:00AM  
Artelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update
GlobeNewswire
Dec-09-19 08:30AM  
Artelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors
GlobeNewswire
Nov-25-19 08:00AM  
Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
GlobeNewswire -8.13%
Nov-18-19 08:30AM  
Artelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
GlobeNewswire
Nov-14-19 09:00AM  
Artelo Biosciences to Present at the Annual Investival Showcase in London
GlobeNewswire
Oct-29-19 08:30AM  
Artelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13
GlobeNewswire -5.65%
Oct-22-19 09:00AM  
Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
GlobeNewswire
Sep-18-19 08:00AM  
Artelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine
GlobeNewswire
Sep-11-19 09:00AM  
Artelo Biosciences to Present at the Fall Investor Summit in New York City on September 17th
ACCESSWIRE +7.29%
Sep-04-19 01:34PM  
What Percentage Of Artelo Biosciences, Inc. (NASDAQ:ARTL) Shares Do Insiders Own?
Simply Wall St.
Jul-15-19 04:01PM  
Artelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
GlobeNewswire
Jul-10-19 07:23AM  
Cannabis stocks dragged down by CannTrusts losses after cannabis seizure
MarketWatch -8.10%
Jun-25-19 01:00PM  
Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option
GlobeNewswire -6.69%
May-08-19 04:05PM  
Artelo Biosciences Retains Crescendo Communications, LLC for Investor Relations Services
ACCESSWIRE
Jan-03-19 07:00AM  
Artelo Biosciences Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services
ACCESSWIRE
Oct-09-18 08:00AM  
New Preclinical Cell-Line Data of Artelo Biosciences' ART27.13 Demonstrate Anti-Proliferative Activity in Tumor Models
ACCESSWIRE
Jul-03-18 08:00AM  
Artelo Biosciences Announces Five Year Commitment To Sponsor The Young Investigator Award At The International Cannabinoid Research Society Annual Symposium
PR Newswire
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system and related signaling pathways. Its product pipeline includes ART27.13, a cannabinoid agonist for the treatment of anorexia associated with cancer; ART12.11, a CBD cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a FABP5 inhibitor for prostate and breast cancer treatment. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is headquartered in La Jolla, California.
open in yahoo | open in reuters | open in google